Colorectal Integrative Adjuvant Chemotherapy Study Of The Impact On The Cost-effectiveness Of Clinical Pathways

Objective:To evaluate the impact of the integrated traditional Chinese and western medicine clinical pathway used for colorectal cancer during adjutant chemotherapy on the work efficiency of hospital operation management and its cost effectiveness analysis, and therefore providing references for the State Administration of Traditional Chinese Medicine to make decisions on choosing high quality clinical pathway.Methods:Using the different time comparison trials method, the trial group consists of the eligible patients and those who used clinical pathway. The control group consists of last year's patients who are eligible but didn't use clinical pathway; Reviewing all the materials and collecting patients'relative hospitalization information including the expenses composition, length of stay, treatment content and the therapeutic effect; Statistically analyzing the expenses, length of stay and the proportion of drug expenses to medical expenses in order to compare the results of two groups, and to evaluate the level of significance of health economics by analyzing its cost effectiveness.Content:The work efficiency and economic operation management:The trial group's total hospitalization expenses is 12774.7±5664.7 yuan, for the control group is 18732.8±12296.3yuan (P< 0.05); The average daily hospitalization cost is 949.7±332.7yuan,1206.6±453.0 yuan (P< 0.05) for the control group; The trial group's drug cost is 8056.1±4271.7 yuan, and it is 13137.9±9530.8 yuan (P< 0.05) for the control group; The trial group's proprietary Chinese medicine cost is 2331.3±1919.2 yuan, and 3815.2±2458.6 yuan (P< 0.05) for the control group; The trial group' s the proportion of drug expenses to medical expenses is 2.0±1.0, and for the control group is 2.8±1.6 (P< 0.05). There are no significant difference between the two group's length of stay, western medicine expense, medical expense, test cost, radiation cost within the statistical analysis, but only shows trend in reducing the cost and rising in Chinese herbal medicine. The Cost Effectiveness Analysis:the trial group's CEA is 21689.5 and for the control group is 68054.4. The trial group's C/E value is lower than the control group, and the same conclusion was made after the sensitivity test.Conclusion:The application of "integrated traditional Chinese and western medicine clinical pathway for colorectal cancer during adjutant chemotherapy" for hospital medical management is more advantaged in the concept of health economics. Patients will be able to get the same level of therapeutic effect with lower costs. The relative data of work efficiency and economic operation management shows that clinical pathway is able to save the health resources and improve performance.